Rubraca
(Rucaparib)Phase 3Small molecule
Bristol-Myers SquibbRucaparib is used to treat certain types of ovarian cancer and breast cancer, particularly in patients whose tumors have specific genetic mutations that make them sensitive to this drug.[1] Rubraca is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Rubraca is one of 185 small molecule programs targeting Leiomyosarcoma. It is currently in Phase 3.
7
Indications
60
Total Trials
9
Active Trials
184
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
314 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Nizoral
WWim Janssens
Phase 3
Verzenio
Eli LillyPhase 3
Rubraca
Bristol-Myers SquibbPhase 3
Acetylsalicylic Acid
BayerPhase 3
Lhrha
Johnson & JohnsonPhase 3
Luteinizing Hormone Releasing Hormone
UUS Department of Veterans Affairs
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Jatenzo
GGrupo Espanol de Tumores Neuroendocrinos
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer9 trials
Show 6 more trials
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Active, not recruiting·—·Phase 1/2·NCT04253262·13 enrolled
Ovarian Cancer6 trials
Show 3 more trials
Bevacizumab3 trials
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Active, not recruiting·—·Phase 2·NCT02873962·73 enrolled
Primary Peritoneal Cancer3 trials
28 more indications
Interaction2 trials
Endometrial Cancer2 trials
Solid Tumor2 trials
Solid Tumors2 trials
Non-Small Cell Lung Cancer2 trials
Pancreatic Cancer2 trials
Gastric Cancer2 trials
Urothelial Carcinoma1 trial
Triple Negative1 trial
Triple-Negative Breast Cancer1 trial
Pain1 trial
Biliary Tract Cancer1 trial
Biliary Cancer1 trial
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Active, not recruiting·—·Phase 1/2·NCT03337087·18 enrolled
Efficacy and Safety1 trial
Esophageal Adenocarcinoma1 trial
Advanced Malignancies1 trial
Absorption1 trial
Fallopian Tube Cancer1 trial
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT03462212·290 enrolled
Small Cell Lung Cancer1 trial
Mesothelioma, Malignant1 trial
Unspecified2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rucaparib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- PARP 1, 2 and 3 Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company